SMAD2 and cancer: If not inhibited by endogenous (e.g., Smad6 and Smad7) or pharmacological (e.g., galunisertib or SB-431542) agents, increased TGF-β-Smad2/3 signaling activity in cancer cells induce cancer cell migration and invasion [13].